Celltrion/ImClone Systems
Transaction details
The proposed acquisition by Celltrion, Inc., through Celltrion USA, Inc., of sole control of ImClone Systems LLC has been cleared by the Competition and Consumer Protection Commission.
Case details
- Notification date:15 October 2025
- Publication date:15 October 2025
- Economic sector:Manufacturing - C
- Economic sub-sector:Manufacture of pharmaceuticals - C.21
- Simplified merger:Yes
- Outcome:Cleared
Documents
M.25.065 Merger AnnouncementPDF | 130 KBM.25.065 Merger Announcement PDF | 130 KB - Opens in new window
M.25.065 DeterminationPDF | 236 KBM.25.065 Determination PDF | 236 KB - Opens in new window
Timetable
Parties Involved
Celltrion, Inc.
Celltrion, Inc. is a is a publicly traded South Korean biopharmaceutical company engaged in the development and global supply of biosimilars, biologics and small molecule drugs.
Celltrion USA, Inc.
Celltrion USA, Inc. is a Delaware-incorporated subsidiary of Celltrion, Inc. Celltrion USA, Inc. is active in the distribution and regulatory management of Celltrion, Inc.'s pharmaceutical products in the United States. Celltrion USA, Inc. has a presence in the State through its subsidiary, Celltrion Healthcare Ireland Limited.
ImClone Systems LLC
ImClone Systems LLC is incorporated as a limited liability company in Delaware, United States. ImClone Systems LLC is active in the pharmaceutical sector through its biopharmaceutical manufacturing facility in Branchburg, New Jersey which produces active pharmaceutical ingredients (APIs).
Contacts
